Hello and Welcome to Patientsville.com, Your Source for all NATEGLINIDE information. We are dedicated to provide You with NATEGLINIDE safety information. Learn about NATEGLINIDE serious adverse events reported to Food and Drug Administration (FDA).
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
NATEGLINIDE Safety Reports
Total NATEGLINIDE reports: 26.NATEGLINIDE FDA safety alerts: No.
Reported deaths: 3 Reported hospitalizations: 23.
Take NATEGLINIDE Side Effects Survey or Share Your NATEGLINIDE Story. Read More Here.
Physician from AUSTRALIA reported NATEGLINIDE problem on Dec 22, 2006. Female patient, 74 years of age, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: headache, pleurisy, pneumonia. NATEGLINIDE dosage: unknown. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from UNITED KINGDOM on Feb 08, 2007. Male patient, 59 years of age, weighting 137.8 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension, hypercholesterolaemia and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: convulsion, fall, hypoglycaemia. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, ADIZEM, SIMVASTATIN. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported NATEGLINIDE problem on Apr 12, 2007. Male patient, 74 years of age, was diagnosed with diabetes mellitus non-insulin-dependent and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, gastric cancer, gastric operation, gastric ulcer, gastrooesophageal reflux disease. NATEGLINIDE dosage: 180 MG/DAY. During the same period patient was treated with ACTOS, TAKEPRON, KINEDAK, AMARYL. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from JAPAN on Apr 24, 2007. Male patient, 74 years of age, was diagnosed with diabetes mellitus non-insulin-dependent and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, gastric cancer, gastric operation, gastric ulcer, gastrooesophageal reflux disease. NATEGLINIDE dosage: 180 MG/DAY. During the same period patient was treated with ACTOS, TAKEPRON, KINEDAK, AMARYL. Patient was hospitalized. Patient recovered.
Physician from CHILE reported NATEGLINIDE problem on Apr 26, 2007. Male patient, 69 years of age, weighting 191.8 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: angina unstable, arterial injury, arterial occlusive disease, cardiac enzymes increased, chest pain, disease progression, myocardial infarction. NATEGLINIDE dosage: unknown. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from UNITED STATES on May 07, 2007. Male patient, 77 years of age, weighting 144.0 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: abdominal discomfort, abdominal distension, abdominal tenderness, benign colonic neoplasm, bradycardia, cardiac pacemaker insertion, colectomy, disease progression, inflammation. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
Physician from RUSSIAN FEDERATION reported NATEGLINIDE problem on May 10, 2007. Female patient, 59 years of age, weighting 217.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: angina pectoris, autoimmune thyroiditis, blood cholesterol increased, cardiac failure, chest pain, coronary artery disease, dyspnoea, hepatic steatosis, high density lipoprotein decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from RUSSIAN FEDERATION on May 17, 2007. Female patient, 59 years of age, weighting 217.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: angina pectoris, autoimmune thyroiditis, blood cholesterol increased, cardiac failure, chest pain, coronary artery disease, dyspnoea, hepatic steatosis, high density lipoprotein decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported NATEGLINIDE problem on May 24, 2007. Female patient, 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: loss of consciousness. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, ATENOLOL. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from CHILE on June 07, 2007. Male patient, 69 years of age, weighting 191.8 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: angina unstable, arterial injury, arterial occlusive disease, cardiac enzymes increased, chest pain, disease progression, glucose tolerance impaired, myocardial infarction, vascular bypass graft. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported NATEGLINIDE problem on June 15, 2007. Male patient, 65 years of age, was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: pancreatic carcinoma. NATEGLINIDE dosage: unknown. Patient died on 03/02/2006.
NATEGLINIDE problem was reported by a Physician from UNITED STATES on June 14, 2007. Female patient, 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: dizziness, loss of consciousness, weight decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, ATENOLOL. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported NATEGLINIDE problem on June 15, 2007. Female patient, 69 years of age, was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: lung neoplasm malignant. NATEGLINIDE dosage: unknown. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from JAPAN on June 26, 2007. Male patient, 65 years of age, was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, ascites, aspartate aminotransferase increased, bile duct stent insertion, bile duct t-tube insertion, biliary dilatation, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased. NATEGLINIDE dosage: unknown. During the same period patient was treated with METFORMINE. Patient was hospitalized. Patient died on 03/02/2006.
Consumer or non-health professional from UNITED KINGDOM reported NATEGLINIDE problem on Aug 24, 2006. Female patient, 66 years of age, was diagnosed with diabetes mellitus non-insulin-dependent and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: dizziness, dyspnoea, fluid retention, food craving, nausea, weight increased. NATEGLINIDE dosage: 60 MG, TID. During the same period patient was treated with AQUEOUS CREAM, ASPIRIN, EMULSIDERM, FLUARIX, LORATADINE, METFORMIN HYDROCHLORIDE, PNEUMOVAX, RAMIPRIL. Patient recovered.
NATEGLINIDE problem was reported by a Physician from JAPAN on July 05, 2007. Male patient, 65 years of age, was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, ascites, aspartate aminotransferase increased, bile duct stent insertion, bile duct t-tube insertion, biliary dilatation, blood alkaline phosphatase increased, blood bilirubin increased, blood chloride decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with METFORMINE. Patient was hospitalized. Patient died on 03/02/2006.
Health Professional from JAPAN reported NATEGLINIDE problem on Aug 03, 2007. Male patient, 61 years of age, was diagnosed with diabetes mellitus and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: altered state of consciousness, blood albumin decreased, blood pressure decreased, body mass index decreased, body temperature decreased, decreased appetite, diarrhoea, electrocardiogram abnormal, glycosylated haemoglobin increased. NATEGLINIDE dosage: 270 MG, UNK. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from UNITED STATES on Aug 09, 2007. Female patient, 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: dizziness, loss of consciousness, weight decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, ATENOLOL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported NATEGLINIDE problem on Aug 09, 2007. Female patient, 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: dizziness, loss of consciousness, weight decreased. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, ATENOLOL. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Health Professional from JAPAN on Aug 10, 2007. Male patient, 61 years of age, was diagnosed with diabetes mellitus and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: altered state of consciousness, blood albumin decreased, blood pressure decreased, body mass index decreased, body temperature decreased, decreased appetite, diarrhoea, electrocardiogram abnormal, glycosylated haemoglobin increased. NATEGLINIDE dosage: 270 MG, UNK. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported NATEGLINIDE problem on Aug 22, 2007. Male patient, 74 years of age, weighting 227.1 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: cervical vertebral fracture, contusion, fall, hypotension, loss of consciousness, skin laceration, syncope. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, FELODIPINE. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Pharmacist from JAPAN on Aug 16, 2007. Female patient was diagnosed with diabetes mellitus and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: dizziness, pancreatitis. NATEGLINIDE dosage: 270 MG, UNK. During the same period patient was treated with MICARDIS, BASEN. Patient recovered.
Health Professional from JAPAN reported NATEGLINIDE problem on Aug 30, 2007. Male patient, 61 years of age, was diagnosed with diabetes mellitus and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: altered state of consciousness, bladder irrigation, blood albumin decreased, blood creatinine decreased, blood potassium decreased, blood sodium decreased, body mass index decreased, decreased appetite, diarrhoea. NATEGLINIDE dosage: 270 MG QD. During the same period patient was treated with GLUCOBAY, MELBIN, FAMOTIDINE, ALDACTONE, LASIX, METHYCOBAL. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from UNITED KINGDOM on Sept 04, 2007. Male patient, 68 years of age, weighting 196.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: abdominal pain, nephrolithiasis, ureteral stent insertion. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
Physician from UNITED KINGDOM reported NATEGLINIDE problem on Sept 11, 2007. Male patient, 68 years of age, weighting 196.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: abdominal pain, nephrolithiasis, renal colic, ureteral stent insertion. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN. Patient was hospitalized. Patient recovered.
NATEGLINIDE problem was reported by a Physician from UNITED STATES on Sept 18, 2007. Male patient, 67 years of age, weighting 267.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with NATEGLINIDE. After drug was administered, patient experienced the following problems/side effects: arrhythmia, disease progression, dizziness, extrasystoles, implantable defibrillator insertion, palpitations, presyncope, sinus bradycardia, ventricular extrasystoles. NATEGLINIDE dosage: unknown. During the same period patient was treated with VALSARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE, LASIX. Patient was hospitalized. Patient recovered.